Vanguard Personalized Indexing Management LLC Increases Stock Holdings in Dr. Reddy’s Laboratories Ltd $RDY

Vanguard Personalized Indexing Management LLC raised its holdings in Dr. Reddy’s Laboratories Ltd (NYSE:RDY) by 19.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 351,469 shares of the company’s stock after buying an additional 56,760 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Dr. Reddy’s Laboratories were worth $4,914,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of RDY. JPMorgan Chase & Co. raised its position in shares of Dr. Reddy’s Laboratories by 157.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 5,910,786 shares of the company’s stock valued at $88,839,000 after purchasing an additional 3,617,435 shares during the last quarter. Robeco Institutional Asset Management B.V. lifted its position in Dr. Reddy’s Laboratories by 13.6% during the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 12,163,428 shares of the company’s stock worth $182,816,000 after acquiring an additional 1,452,192 shares during the period. Acadian Asset Management LLC raised its stake in shares of Dr. Reddy’s Laboratories by 43.8% in the second quarter. Acadian Asset Management LLC now owns 2,116,358 shares of the company’s stock worth $31,798,000 after purchasing an additional 644,835 shares during the last quarter. Creative Planning raised its position in Dr. Reddy’s Laboratories by 105.0% during the 2nd quarter. Creative Planning now owns 1,094,932 shares of the company’s stock worth $16,457,000 after buying an additional 560,823 shares during the last quarter. Finally, Balyasny Asset Management L.P. purchased a new position in shares of Dr. Reddy’s Laboratories during the second quarter worth $5,024,000. Hedge funds and other institutional investors own 3.85% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings lowered shares of Dr. Reddy’s Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, January 16th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $16.90.

Dr. Reddy’s Laboratories Price Performance

Shares of NYSE:RDY traded down $0.35 during trading on Wednesday, reaching $13.37. 74,479 shares of the company’s stock traded hands, compared to its average volume of 1,622,922. The firm has a market cap of $11.16 billion, a PE ratio of 17.34, a P/E/G ratio of 12.18 and a beta of 0.37. Dr. Reddy’s Laboratories Ltd has a fifty-two week low of $12.26 and a fifty-two week high of $16.17. The company has a quick ratio of 1.38, a current ratio of 1.88 and a debt-to-equity ratio of 0.03. The company has a 50-day simple moving average of $13.82 and a 200-day simple moving average of $14.07.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its quarterly earnings data on Wednesday, January 21st. The company reported $0.16 EPS for the quarter, meeting the consensus estimate of $0.16. The company had revenue of $969.81 million for the quarter, compared to analyst estimates of $963.84 million. Dr. Reddy’s Laboratories had a return on equity of 15.89% and a net margin of 16.41%. As a group, analysts predict that Dr. Reddy’s Laboratories Ltd will post 0.8 earnings per share for the current year.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Ltd. is an India‐based multinational pharmaceutical company that develops, manufactures and markets a wide range of pharmaceutical products and services. Established in 1984 by the late Dr. Kallam Anji Reddy, the company has grown into a diversified healthcare enterprise offering generic and proprietary medicines, active pharmaceutical ingredients (APIs), biosimilars and custom research and manufacturing services (CRAMS). Its portfolio spans therapeutic areas such as oncology, cardiovascular care, dermatology, gastroenterology and pain management.

The company’s core activities include the development and commercialization of cost‐effective generic treatments for branded drugs that have lost patent protection, along with in‐house research into innovative molecule development.